-
2 months ago | 
healio.com | Gabrielle Capaldo |Kristen Dowd |Joel M. Gelfand |Mark Lebwohl
Key takeaways: Skin diseases, such as psoriasis and hidradenitis suppurativa, bring with them severe cardiovascular risks. Addressing these risks through holistic means, including anti-obesity drugs, may improve health. In honor of American Heart Month, Healio Dermatology interviewed experts and explored the connection between skin disease and heart health.
-
Nov 27, 2024 | 
jamanetwork.com | April W. Armstrong |Mark Lebwohl |Richard Warren |Howard Sofen
Key PointsQuestion
What is the safety and efficacy of continuous treatment with deucravacitinib over a 3-year period? Findings
In this integrated analysis of the phase 3 POETYK PSO-1, PSO-2, and nonrandomized long-term extension trials in 1519 patients with moderate to severe plaque psoriasis treated through 3 years with 1 or more doses of deucravacitinib, no new safety signals were observed compared with the first year.
-
Oct 15, 2024 | 
dovepress.com | Boni E. Elewski |Mark Lebwohl
Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 17 Authors Elewski B, Lebwohl MG Received 15 October 2024 Accepted for publication 15 October 2024 Published 4 November 2024 Volume 2024:17 Pages 2487—2493 DOI https://doi.org/10.2147/CCID.S501061 Checked for plagiarism Yes Editor who approved publication: Dr Scott Fraser Boni Elewski,1 Mark G Lebwohl2 1Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, USA; 2Icahn School of Medicine at...
-
Jul 19, 2024 | 
academic.oup.com | Songtao Tan |Hira Ghani |Polat Goktas |Mark Lebwohl
-
Jun 13, 2024 | 
healio.com | Richard Gawel |Kristen Dowd |Mark Lebwohl
You've successfully added Skin Disorders to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Remibrutinib reduces histamine formation inside of cells. Improvements in itch and hives were seen as early as 1 week.
-
Jun 5, 2024 | 
digitalcommons.library.tmc.edu | Mark Lebwohl |Leon Kircik |Angela Moore |Linda Gold
IMPORTANCE: Once-daily roflumilast cream, 0.3%, a potent phosphodiesterase 4 inhibitor, demonstrated efficacy and was well tolerated in a phase 2b trial of patients with psoriasis. OBJECTIVE: To evaluate the efficacy of roflumilast cream, 0.3%, applied once daily for 8 weeks in 2 trials of patients with plaque psoriasis.
-
Apr 26, 2024 | 
hcplive.com | Mark Lebwohl |Saakshi Khattri |Mona Shahriari |Jennifer Soung
April 26, 2024Experts conclude the series discussing how to approach switching psoriasis treatments. Dermatologists discuss their approach to managing patients who have experienced treatment failure. They debate whether to switch to a different class of drug or remain within the same class based on factors such as primary versus secondary failure and individual patient response.
-
Apr 26, 2024 | 
hcplive.com | Mark Lebwohl |Saakshi Khattri |Mona Shahriari |Jennifer Soung
April 26, 2024Experts discuss package warnings associated with bimekizumab and how they inform patients of them. Regarding the warnings in the bimekizumab package insert, specifically about suicidal ideation and elevated liver enzymes, different approaches are taken by physicians in discussing these potential side effects with patients, but each aim to address those concerns with their patients.
-
Apr 26, 2024 | 
hcplive.com | Mark Lebwohl |Saakshi Khattri |Mona Shahriari |Jennifer Soung
April 26, 2024Experts discuss bimekizumab for the treatment of psoriasis highlighting is efficacy over other treatments. Bimekizumab, a newly approved biologic for psoriasis, differs from existing biologics in that it blocks both IL-17A and IL-17F. This dual mechanism of action distinguishes it from previous IL-17 blockers, which targeted IL-17A alone.
-
Apr 19, 2024 | 
hcplive.com | Mark Lebwohl |Saakshi Khattri |Mona Shahriari |Jennifer Soung
April 19, 2024Experts discuss the warnings regarding IL-17 blockers and inflammatory bowel disease. In discussing the issue of inflammatory bowel disease (IBD) in patients receiving IL-17 blockers, the experts acknowledge the cautionary language in package inserts based on early studies. While there was initial concern about potential exacerbation of IBD with IL-17 blockers, subsequent real-world data have not shown increased or worsened IBD symptoms.
